Lyell Immunopharma Inc investor relations material

Lyell Immunopharma Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. It develops BioPulse treatment which modulates the expression of tumor antigens to amplify cellular immunotherapy. The company offers B-chimeric antigen receptor (CAR) to stimulate infiltration of T cells into cancer cells. Its cytokine treatments include OncoPuls, which aims at generating self-amplifying CAR populations expressing a single target antigen; and UniPuls, which has the potential to express multiple antigens and can be used with conventional chemotherapy formulations. Its other product is intratumoral T cell vaccines, which targets epithelial cancers. The company utilizes its proprietary technologies in the development of novel therapeutics for the treatment of antibody-refractory cancers. It also focuses on the discovery and development of programmable immune cell therapies using Autologous Dendritic Cells (DCs) and T cells; Identification of Biotherapeutics for Cancer; Antibody Directed Selection/Activation of T Cells (ADSTAT); and Novel Cancer Therapeutic Products Development Platforms.